SuspendedNot Applicable

Creatine Supplementation for Improved Voice Performance in the Elderly

Stopped: Project is on indefinite hold due to a lack of funding

United States20 participantsStarted 2026-05-01

Plain-language summary

The primary objective of this study is to determine if creatine supplementation improves acoustic, auditory perceptual, physiologic, and patient-reported outcome measures in patients over 65 years of age. In the study, 20 participants will be enrolled and randomly assigned to receive either creatine or placebo.

Who can participate

Age range65 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 65 years or older
✓. Desiring to participate in voice therapy

Exclusion criteria

✕. Lesions or abnormalities of the larynx not attributable to normal aging
✕. Pre-existing renal disease
✕. Pre-existing liver disease
✕. Congestive heart failure
✕. Blood urea nitrogen (BUN), creatine, alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) over reference range in the last 6 months
✕. Concurrent medication associated with reduced renal clearance (e.g. Nonsteroidal Anti-inflammatory Drugs (NSAIDs), metformin)
✕. History of prior vocal fold augmentation procedures
✕. Cognitive disability

What they're measuring

Change from Baseline in Voice Handicap Index (VHI)-10 Scores

Timeframe: Baseline, Week 10

Average Expert Rating of Change in Mucosal Wave

Timeframe: Week 10

Average Expert Rating of Change in Vocal Fold Atrophy

Timeframe: Week 10

Average Expert Rating of Change in Glottal Closure

Timeframe: Week 10

Average Phonatory Pressure during Aerodynamic Analysis of Voice

Timeframe: Up to Week 10

Average Decibel (dB) Output during Aerodynamic Analysis of Voice

Timeframe: Up to Week 10

Trial details

NCT IDNCT05856916

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Presbyphonia trials

Plain-language summary

Who can participate

Age range65 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 65 years or older
✓. Desiring to participate in voice therapy

Exclusion criteria

✕. Lesions or abnormalities of the larynx not attributable to normal aging
✕. Pre-existing renal disease
✕. Pre-existing liver disease
✕. Congestive heart failure
✕. Blood urea nitrogen (BUN), creatine, alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) over reference range in the last 6 months
✕. Concurrent medication associated with reduced renal clearance (e.g. Nonsteroidal Anti-inflammatory Drugs (NSAIDs), metformin)
✕. History of prior vocal fold augmentation procedures
✕. Cognitive disability

What they're measuring

Change from Baseline in Voice Handicap Index (VHI)-10 Scores

Timeframe: Baseline, Week 10

Average Expert Rating of Change in Mucosal Wave

Timeframe: Week 10

Average Expert Rating of Change in Vocal Fold Atrophy

Timeframe: Week 10

Average Expert Rating of Change in Glottal Closure

Timeframe: Week 10

Average Phonatory Pressure during Aerodynamic Analysis of Voice

Timeframe: Up to Week 10

Average Decibel (dB) Output during Aerodynamic Analysis of Voice

Timeframe: Up to Week 10